Revance Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018
Period Ending	Sep '23 Sep 30, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	Dec '19 Dec 31, 2019	Dec '18 Dec 31, 2018
Revenue	25.93	24.41	20.99	9.09	3.16	0.97
Revenue Growth (YoY)	6.69%	16.30%	130.99%	187.23%	226.19%	-
Cost of Revenue	70.96	36.25	26.29	11.09	4.23	2.24
Gross Profit	-45.03	-11.84	-5.3	-2	-1.07	-1.27
Selling, General & Admin	54.27	51.95	33.93	10.53	7.12	4.7
Research & Development	8.79	9.31	2.91	1.23	0.98	0.43
Operating Expenses	63.06	61.26	36.84	11.76	8.1	5.13
Operating Income	-108.09	-73.09	-42.14	-13.76	-9.17	-6.4
Interest Expense	-14.45	-16.27	-13.37	-2.98	-0.58	-0.14
Interest & Investment Income	1.3	1.31	-	-	-	-
Other Non Operating Income (Expenses)	2.14	19.42	-34.17	-20.91	0.05	-0.03
EBT Excluding Unusual Items	-119.11	-68.63	-89.68	-37.65	-9.69	-6.57
Merger & Restructuring Charges	-	-	-9.1	-	-	-
Other Unusual Items	19.85	83.8	-1.99	-	-	-
Pretax Income	-104.14	15.17	-100.77	-37.65	-9.69	-6.57
Net Income	-104.14	15.17	-100.77	-37.65	-9.69	-6.57
Preferred Dividends & Other Adjustments	-	-	-	-	2.62	1.96
Net Income to Common	-104.14	15.17	-100.77	-37.65	-12.31	-8.53
Shares Outstanding (Basic)	5	4	3	2	0	0
Shares Outstanding (Diluted)	5	4	3	2	0	0
Shares Change (YoY)	27.90%	42.06%	100.23%	824.75%	-	-
EPS (Basic)	-19.66	3.93	-33.44	-25.02	-75.65	-52.39
EPS (Diluted)	-19.66	3.19	-33.44	-25.02	-75.65	-52.39
Free Cash Flow	-93.26	-112.44	-69.05	-18.24	-13.88	-6.81
Free Cash Flow Per Share	-17.61	-26.27	-22.92	-12.12	-85.28	-41.83
Gross Margin	-173.69%	-48.49%	-25.25%	-22.00%	-33.79%	-130.93%
Operating Margin	-416.91%	-299.41%	-200.76%	-151.40%	-289.67%	-660.21%
Profit Margin	-401.65%	62.14%	-480.03%	-414.32%	-389.06%	-878.87%
Free Cash Flow Margin	-359.69%	-460.58%	-328.94%	-200.69%	-438.59%	-701.75%
EBITDA	-105.56	-71.27	-41.27	-13.4	-8.93	-6.2
EBITDA Margin	-	-291.95%	-196.59%	-147.41%	-282.33%	-
D&A For EBITDA	2.54	1.82	0.87	0.36	0.23	0.2
EBIT	-108.09	-73.09	-42.14	-13.76	-9.17	-6.4
EBIT Margin	-	-299.41%	-200.76%	-151.40%	-289.67%	-
Advertising Expenses	-	0.58	0.26	0.05	0.01	0.01

Updated Nov 20, 2023. Source: S&P Global Market Intelligence. Standard template. Financial Sources.